Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA to Host Conference Call to Present Initial Results From XOMA 052 Clinical Trial in Behcet's Disease

Jun 10, 2010 5:00pm EDT

Abstract Published on Initial Results From XOMA 052 Clinical Trial in Behcet's Disease

May 12, 2010 2:38pm EDT

XOMA Reports First Quarter 2010 Financial Results

May 06, 2010 4:02pm EDT

XOMA 052 Mechanism of Action Results Published in Journal of Biological Chemistry

Apr 30, 2010 1:30pm EDT

XOMA to Announce 2010 First Quarter Financial Results and Host Webcast Conference Call on May 6

Apr 29, 2010 6:09pm EDT

XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in Human Myeloma Cells

Apr 19, 2010 5:27pm EDT

XOMA Receives $1 Million Milestone Payment From Takeda Pharmaceutical

Apr 15, 2010 8:00am EDT

XOMA Issued Two New U.S. Patents for Methods of Treating Type 2 Diabetes and Inflammatory Diseases Using Interleukin-1 Beta Antibodies

Apr 13, 2010 6:00am EDT

Data on XOMA 052 to be Presented at the American Association of Cancer Research Annual Meeting

Apr 09, 2010 8:00am EDT

XOMA Receives Anticipated Notice of Non-Compliance From NASDAQ

Mar 16, 2010 5:30pm EDT
RSS
  • Prev
    • 1...
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top